Brief: Lipocine Highlights Promising Interim Safety Profile In Phase 3 Trial Of Lpcn 1154 In Postpartum Depression (Ppd)
18/11/2025 13:16
Lipocine Inc LPCN.O: LIPOCINE HIGHLIGHTS PROMISING INTERIM SAFETY PROFILE IN PHASE 3 TRIAL OF LPCN 1154 IN POSTPARTUM DEPRESSION (PPD) LIPOCINE INC: TOPLINE RESULTS ARE ON TRACK FOR Q2 OF 2026 LIPOCINE INC: PER DRUG SAFETY MONITORING BOARD (DSMB) MEETING EVALUATING ONE-THIRD OF PLANNED PARTICIPANTS, STUDY TO CONTINUE AS PLANNED LIPOCINE INC - NO DOSE REDUCTIONS OR DRUG-RELATED SAES REPORTED Source text: ID:nPn3wvHHHa Further company coverage: LPCN.O
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy